BRCA genetic testing and treatment patterns for patients with HER2-negative early-stage breast cancer in the US community setting
{{output}}
Background: Adjuvant olaparib has been approved in the US since 2022 for patients with high-risk HER2-negative early-stage breast cancer (eBC) with germline mutation in BRCA1 or BRCA2 (gBRCAm), and contemporary real-world data ar... ...
